INDIVIDUALIZATION OF ADJUVANT THERAPY OF BREAST CANCER


Cite item

Full Text

Abstract

In 2010, therapy for breast cancer was determined by the fundamental biology of the tumor as measured by such prognostic markers of outcome as status of hormone receptors, HER2 expression and incremental molecular typing. These bioassays enlarge traditional staging in determining the risk of relapse, which had previously been the sole determinant for treatment planning. Small tumors with signs of high risk of recurrence require aggressive adjuvant therapy, whereas higher stage tumors with favorable biological characteristics may not require such therapy. Important prospective clinical trials integrating traditional and new markers of risk are currently under way to optimization of individualized treatment of patients with early (operable) breast cancer.

References

  1. Sotoriou C, Puzlai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
  2. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
  3. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-28.
  4. National Comprehensive Cancer Network. NCCN: Clinical practice guidelines in oncology 2010, www.nccn.org.
  5. Fracheboud J, Otto SJ, van Dijck JA, et al. Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 2004;91:861-67.
  6. Vacek PM, Geller BM, Weaver DL, et al. Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975-1999. Cancer 2002;94:2160-68.
  7. American Cancer Society. Breast Cancer Facts & Figures, 2007-2008. Atlanta, GA: American Cancer Society, Inc. 2008.
  8. Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004;22:1630-37.
  9. Rosen PP, Groshen S, Kinne DW, et al. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1NOMO/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11:2090-100.
  10. Stierer M, Rosen HR, Weber R, et al. Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obslet 1992;175:151-60.
  11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
  12. Ravdin PM, Charmless GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers A review. Gene 1995;159:19-27.
  13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
  14. Romond EH, Perez КL, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-poeitive breast cancer. N Engl J Med 2005;353:1673-84.
  15. Slamon D, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC ≥ T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC ≥ TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [abstract A-52]. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006.
  16. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
  17. Viani GA, Afonao SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 2007;7:153.
  18. Black D, Younger J, Martei Y, et al. Recurrence risk in Tla-b, node-negative, HER2 positive breast cancer. Breast Cancer Res Treat 2006;100(l):abstr 2037.
  19. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pTINOMO breast cancer: A nationwide population-based study. Clin Cancer Res 2003;9:923-30.
  20. Tovey SM, Brown S, Doughty JC, et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumors. Br J Cancer 2009;100:680-83.
  21. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26:5697-6704.
  22. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:1090-96.
  23. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, et al. Treatment of node-negative infra-centrimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol 2009;27:abstr 517.
  24. McArthur III, Morris PG, Patil S, et al. Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer study rationale (abstract 228). Proc Breast Symp 2009.
  25. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
  26. Berry DA, Cirricincione C, Henderson 1С, et al. Estrogen-receptor status and outcomes of modem chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1668.
  27. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055.
  28. Goldstein L, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic risk factors. J Clin Oncol 2008;25:4063-171.
  29. Albain KS, Barlow WE, Shack S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomized trial. Lancet Oncol 2010;11:55-65.
  30. Cuzick J, Dowsett M. Wale С, et al. Prognostic value of a combined ER, PgR Ki67, HER2 immunochemical (IHC4) score and comparison with the GHI recurrence score - results for TansATAC [abstract 74]. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006.
  31. Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009;116:295-302.
  32. Cardoso F, Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: The MINDACT Trial. J Clin Oncol 2008;26:729-35.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies